Evelo touts PhII win for in­flam­ma­tion pro­gram; In­novent, An­Heart claim in­ter­im PhII suc­cess in NSCLC

Flag­ship’s Evelo Bio­sciences is tout­ing a win Mon­day in a Phase II study ex­am­in­ing an oral treat­ment for in­flam­ma­to­ry dis­eases.

Re­searchers saw a sta­tis­ti­cal­ly sig­nif­i­cant …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER